Eris Lifesciences betting on insulin expertise to boost its GLP-1 play

“We have a very successful insulin business with a market share of close to 10% in the country. Any company that sells well-selling GLP-1 was able to do GLP-1 very well.”MintIn an interview.

Danish drug producer Novo Nordisk, an innovative of Blockbuster anti-bezity drugs Özempic and Wegovy, is also an insulin market leader with more than 50% market share in India. Weight loss drugs market is over in India La600 crore in July 2025.

Vaidanathan, insulin business only sells the product that goes beyond selling a patient service and care platform, he said. “… There is active support by ERIS in the patient’s residence… Considering this insulin platform, we are more confident that we can achieve the success of GLP-1, because it will continue on this platform.” Eris says that they have a “one species” patient service model that they train patients to use insulin, and that Novo has a service model and a wide doctorate network.

GLP-1 or glucagon-like peptide-1 agonists are a class of drugs used to treat the GLP-1 hormone produced in the intestine to regulate blood sugar and appetite. Eris plans to rely on third parties for active pharmaceutical components (API), but will eventually bring it within the Semaglid company. It will be connected to third parties for the synthetic Semagluid API.

Eris launched Liraglidide, a GLP-1 in India last year, and plans to be among the first launch wave for Generik Semaglutid, who came out of the patent in March 2026.

It’s not just one. The best drug producers, including India’s Dr Rowdy’s, Jepla, Sun Pharma, Zydus Lifesciences and Natco, are preparing to start the generic Semagludi next year.

The company also has an independent insulin analogs and insulin analogs with GLP-1 combinations in pre-clinical and clinical studies.

Insulin dominance

Earlier this year, Novo Nordisk announced the return of pen -full versions of the best -selling human Mixtard insulin. Although vial versions will still be sold, this opens a big market for domestic players to fill the country. La4,500 CRORE INSULIN MARKET.

Eris, as a part of a larger agreement to obtain the branded formulation business last year, Briocon Biologics’ten silenced and purchased basalog brands. He also sells Xsulin through a common initiative with Mj Biopharma.

In addition to the innovators Novo Nordisk Vesanoffi, who dominated the Indian insulin market, Lupine, who bought Eli Lilly’s Huminsülin brand last year, is an important domestic player.

Vaidanathan, “In other words, insulins and GLP-1s this democratization will take place. The ball rolled,” he said.

Eris expects to see the increasing sales from the Record Human Insulin (RHI) pen products in November and December when the innovative inventory is exhausted.

The company also plans to create insulin and GLP-1 production at a later stage.

The company started to produce insulin bottles at the Bhopal facility in Q1FY26 and is waiting to start production by Q4FY26.

Vaidanathan said, “When we think that a product is great and strategically important, we bring it within the company,” he said.

Eris Lifesciences reported the results of the third quarter 26 results on Tuesday and consolidated income increased by 7.4% annually La773 Crore. FAVÖK for the quarter La277 Crore increased by 11% with 36% EBITDA margin.

Net profit increased by 41% La125 Crore. The drug producer focused on increasing profitability and separation of debt in 26 financial years.

Vaidanathan said, “All this will be accompanied by a significant acceleration in EPS (earnings per share) and return rates,” Vaidanathan said. EPS in the quarter La9.2 and the company is waiting for 50% EPS growth in the financial year.

Company’s net debt in the first quarter 26 La2,317 CRORE and aims to reduce debt La1,800 crore by the end of the year.